Comparing 2 hypotheses side-by-side
## Mechanistic Overview Complement C1q Mimetic Decoy Therapy starts from the claim that modulating C1QA within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The complement component 1q (C1q) represents a critical molecular bridge between innate immunity and synaptic plasticity in the central nervous system. C1q is a hexameric glycoprotein composed of three distinct polypeptide chains (C1qA,
## Mechanistic Overview Purinergic P2Y12 Inverse Agonist Therapy starts from the claim that modulating P2RY12 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The P2Y12 receptor, encoded by the P2RY12 gene, represents a critical component of microglial surveillance and activation machinery in the central nervous system. This Gi/Go-coupled purinergic receptor responds to extracellular ad
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Complement C1q Mimetic Decoy T | Purinergic P2Y12 Inverse Agoni |
|---|---|---|
| Mechanistic | 0.750 | 0.750 |
| Evidence | 0.680 | 0.650 |
| Novelty | 0.820 | 0.800 |
| Feasibility | 0.620 | 0.700 |
| Impact | 0.780 | 0.720 |
| Druggability | 0.580 | 0.850 |
| Safety | 0.650 | 0.550 |
| Competition | 0.850 | 0.750 |
| Data | 0.720 | 0.600 |
| Reproducible | 0.580 | 0.580 |
| KG Connect | 0.728 | 0.705 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
Curated mechanism pathway diagrams from expert analysis
graph TD
subgraph Disease["Pathological State"]
A["Neurodegeneration Trigger"] -->|"upregulates"| B["C1QA Gene Expression"]
B -->|"produces"| C["C1q Hexameric Complex"]
C -->|"binds to"| D["Synaptic Eat-Me Signals"]
D -->|"includes"| E["Phosphatidylserine and Amyloid-beta"]
C -->|"activates"| F["Classical Complement Cascade"]
F -->|"generates"| G["C3 Convertase Formation"]
G -->|"produces"| H["C3b Opsonization"]
H -->|"recruits"| I["Microglial CR3 Receptors"]
I -->|"triggers"| J["Synaptic Phagocytosis"]
end
subgraph Therapy["C1q Mimetic Decoy Intervention"]
K["C1q Mimetic Decoy Molecule"] -->|"competes with"| C
K -->|"blocks"| D
L["Therapeutic Administration"] -->|"delivers"| K
M["Decoy Sequestration"] -->|"prevents"| F
end
subgraph Outcome["Clinical Endpoints"]
N["Synaptic Preservation"] -->|"maintains"| O["Cognitive Function"]
P["Reduced Neuroinflammation"] -->|"improves"| Q["Neurological Outcomes"]
R["Biomarker Monitoring"] -->|"tracks"| N
end
K -->|"reduces"| J
M -->|"leads to"| N
M -->|"results in"| P
style A fill:#ef5350,stroke:#333,color:#000
style B fill:#ce93d8,stroke:#333,color:#000
style C fill:#ef5350,stroke:#333,color:#000
style D fill:#ef5350,stroke:#333,color:#000
style E fill:#ef5350,stroke:#333,color:#000
style F fill:#ef5350,stroke:#333,color:#000
style G fill:#4fc3f7,stroke:#333,color:#000
style H fill:#4fc3f7,stroke:#333,color:#000
style I fill:#ef5350,stroke:#333,color:#000
style J fill:#ef5350,stroke:#333,color:#000
style K fill:#81c784,stroke:#333,color:#000
style L fill:#81c784,stroke:#333,color:#000
style M fill:#81c784,stroke:#333,color:#000
style N fill:#ffd54f,stroke:#333,color:#000
style O fill:#ffd54f,stroke:#333,color:#000
style P fill:#ffd54f,stroke:#333,color:#000
style Q fill:#ffd54f,stroke:#333,color:#000
style R fill:#4fc3f7,stroke:#333,color:#000
graph TD
A["Extracellular
ADP/ATP Release"] --> B["P2Y12 Receptor
Activation"]
B --> C["Gi/Go Protein
Coupling"]
C --> D["Adenylyl Cyclase
Inhibition"]
D --> E["Decreased cAMP
Levels"]
E --> F["PI3K/Akt Pathway
Activation"]
F --> G["Rho GTPase
Activation
(Rac1/CDC42)"]
G --> H["Actin Cytoskeletal
Reorganization"]
H --> I["Microglial Process
Extension"]
I --> J["Enhanced Synaptic
Surveillance"]
J --> K["Excessive Synaptic
Pruning"]
K --> L["Neuronal Network
Dysfunction"]
L --> M["Neurodegeneration
Progression"]
N["P2Y12 Inverse
Agonist Therapy"] --> B
N -->|"Blocks"| C
O["Therapeutic
Outcome"] --> L
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,C,D,E normal
class N therapeutic
class I,J,K,L,M pathology
class O outcome
class F,G,H molecular